Oramed Pharmaceuticals
ORMP
27 hedge funds and large institutions have $3.4M invested in Oramed Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 1 closing their positions.
2,003% more capital inflows, than outflows
Capital inflows: $1.03M | Capital outflows: $49.1K
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
200% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 3
23% more funds holding
Funds holding: 22 → 27 (+5)
0.58% more ownership
Funds ownership: 2.06% → 2.64% (+0.58%)
68% less call options, than puts
Call options by funds: $9K | Put options by funds: $28K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$203K |
| 2 |
Millennium Management
New York
|
+$152K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$143K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$120K |
| 5 |
Renaissance Technologies
New York
|
+$100K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
-$40.9K |
| 2 |
Plante Moran Financial Advisors
Southfield,
Michigan
|
-$3K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.75K |
| 4 |
Tower Research Capital (TRC)
New York
|
-$2.5K |
ORMP Hedge Fund Activity: Q4 2017 in Review
27 of the 4,420 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q4 2017, worth a combined $3.4M — up 25% from $2.72M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ORMP positions and 1 closed out — a net gain of 5 holders — while 9 added to existing stakes and 3 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $203K. The largest seller was Wells Fargo, cutting an estimated $40.9K.
- 27 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q4 2017, up from 22 in Q3 2017.
- Funds reported $3.4M of Oramed Pharmaceuticals stock for Q4 2017, up 25% quarter-over-quarter.
- 6 funds opened new Oramed Pharmaceuticals positions in Q4 2017 and 1 closed out, a net change of +5 holders.
- The largest Oramed Pharmaceuticals buyer in Q4 2017 was Morgan Stanley, an estimated $203K added.
- The largest Oramed Pharmaceuticals seller in Q4 2017 was Wells Fargo, an estimated $40.9K sold.
Based on aggregated 13F filings for Q4 2017.